BioNTech SE (BNTX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$98.81

From 52W high−19.51%

Volume1.14M

Market cap$24.13B

P/E (TTM)—

P/S (TTM)8.0x

Div yield—

Key dataSep 18, 2026

Open

$98.81

From 52W high

−19.51%

Volume

1.14M

Market cap

$24.13B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−12.3x

P/E (TTM)

—

RSI (14)

44.2

MomentumView details →

1D Return

−2.64%

YTD Return

+0.96%

SummaryUpdated Jun 1, 2026

BioNTech SE (NASDAQ:BNTX) is a German biotechnology company founded in 2008 and headquartered in Mainz, Germany. The company gained global prominence during the COVID-19 pandemic as the developer of the first approved mRNA-based COVID-19 vaccine in partnership with Pfizer. Originally focused on developing immunotherapies for cancer treatment, BioNTech has evolved into a leading mRNA technology platform company with applications spanning oncology, infectious diseases, and rare diseases. The company went public on NASDAQ in October 2019 and has since established itself as a pioneer in mRNA therapeutics with a robust pipeline of over 20 oncology programs and multiple infectious disease vaccine candidates.

Ask drillr about BioNTech SE →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−12.3x

EV/Sales

4.4x

P/S (TTM)

8.0x

P/B (TTM)

1.2x

ProfitabilityView details →

Gross Margin

70.82%

Net Margin

−64.02%

EBITDA Margin

−35.60%

ROE (TTM)

−9.53%

ROA (TTM)

−8.32%

Asset Turnover

0.13x

GrowthView details →

Revenue YoY

−8.16%

EPS YoY

—

FCF YoY

+124.08%

Revenue CAGR 3Y

−45.80%

EPS CAGR 3Y

−62.82%

EBITDA YoY

—

MomentumView details →

1D Return

−2.64%

YTD Return

+0.96%

1Y Return

−0.11%

RSI (14)

44.2

vs 50D SMA

−1.05%

vs 200D SMA

−1.49%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

7.85x

Quick Ratio

7.80x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$3.70

EPS Surprise

−54.29%

Beats (12Q)

2/12

Next Q EPS Est

$0.86

Avg Surprise (4Q)

−48.36%

Rev Surprise

−33.07%

Financials snapshotView financials →

Revenue (TTM)

2.64B

Net Income (TTM)

−1.69B

Op. CF (TTM)

736.83M

Next earningsNov 3, 2026 →

Latest newsMore news →

Health Canada approved the Pfizer-BioNTech COVID-19 vaccine adapted for the Omicron XBB variant.3d ago

BioNTech and OncoC4 announced updated data from the non-pivotal stage 1 of the PRESERVE-003 Phase 3 trial showing gotistobart nearly doubled median overall survival versus standard-of-care chemotherapy in previously treated squamous non-small cell lung cancer patients.6d ago

Similar companies

特宝生物688278.SH Biocytogen Pharmaceuticals (Beijing) Co., Ltd.02315.HK 天坛生物600161.SH Incyte CorporationINCY Zai Lab Limited09688.HK InnoCare Pharma Limited09969.HK Find similar companies →

Latest newsMore news →

Health Canada approved the Pfizer-BioNTech COVID-19 vaccine adapted for the Omicron XBB variant.3d ago BioNTech and OncoC4 announced updated data from the non-pivotal stage 1 of the PRESERVE-003 Phase 3 trial showing gotistobart nearly doubled median overall survival versus standard-of-care chemotherapy in previously treated squamous non-small cell lung cancer patients.6d ago The U.S. FDA approved the supplemental Biologics License Application for Pfizer and BioNTech's 2026-2027 COVID-19 vaccine formula targeting the XFG variant, for use in adults aged 65 and older and individuals aged 5-64 with high-risk conditions.24d ago